$ACT Recent Headlines Eight charts plot the year in

New Post Public Reply Private Reply Replies (0) Message Board

Dec 30, 2014 at 12:15 PM

$ACT Recent Headlines

Eight charts plot the year in finance 6:00 a.m. Today - Ophir Gottlieb
Here are the best S&P 500 stocks and sectors of 2014 1:52 p.m. Dec. 29, 2014 - Philip van Doorn
2014 was the year that all predictions were wrong 11:29 a.m. Dec. 26, 2014 - Marek Fuchs
GoPro, Adamas climb, Cal-Maine slides 10:06 a.m. Dec. 24, 2014 - MarketWatch
Adamas' stock soars after dementia treatment approval 8:24 a.m. Dec. 24, 2014 - Tomi Kilgore
Second 2% S&P 500 spike signals strong bull trend 11:23 a.m. Dec. 19, 2014 - Michael Ashbaugh
What a week: Botox haze, merger Monday and The Tanned One 9:19 a.m. Nov. 21, 2014 - Marek Fuchs
Valeant's stock rises after new $2 billion buyback plan announced 12:00 p.m. Nov. 20, 2014 - Tomi Kilgore
La-Z-Boy shares rally after earnings beat targets 4:41 p.m. Nov. 18, 2014 - Sue Chang
S&P, Dow ring up records Tuesday 4:35 p.m. Nov. 18, 2014 - Barbara Kollmeyer
Actavis shares outpace buyout target’s gains 12:30 p.m. Nov. 18, 2014 - Russ Britt
S&P 500 registers 42nd record close in skittish market 4:59 p.m. Nov. 17, 2014 - Carla Mozee
Urban Outfitters slides after earnings miss expectations 4:43 p.m. Nov. 17, 2014 - Sue Chang
Valeant says it won’t meet Actavis’s offer 12:18 p.m. Nov. 17, 2014 - Russ Britt
If you're looking big pharma, look no further than Actavis 11:33 a.m. Nov. 17, 2014 - The Trading Deck
Actavis to buy Allergan in $66 billion deal 9:35 a.m. Nov. 17, 2014 - Jonathan D. Rockoff
Actavis confirms to buy Allergan in $66 billion deal 9:30 a.m. Nov. 17, 2014 - Ciara Linnane
Actavis, Allergan close to a deal 8:33 a.m. Nov. 17, 2014 - Jonathan D. Rockoff
Allergan, Actavis near cash-and-stock deal: WSJ 1:48 p.m. Nov. 16, 2014 - Andria Cheng
10 S&P 500 companies with the fastest revenue growth 8:28 a.m. Nov. 11, 2014 - Philip van Doorn

U.S. M&A Seen Staying Robust In 2015, Fueled By Oil 5:38 p.m. Dec. 29, 2014 - Investors Business Daily
The Allergan Acquisition Is A Game-Changer For Actavis: Stock Could Double In Five Years 3:57 p.m. Dec. 29, 2014 - Seeking Alpha
Actavis' Alzheimer's Drug Approved; Bystolic Gets CRL - Analyst Blog 1:20 p.m. Dec. 26, 2014 - Zacks.com
The Bests and Bloopers From the Year in Deal Making 10:04 p.m. Dec. 25, 2014 - The Wall Street Journal Interactive Edition
FDA clears Adamas Alzheimer's drug 8:52 a.m. Dec. 24, 2014 - Seeking Alpha
Pharmacyclics Reveals FDA Action Date for Imbruvica sNDA - Analyst Blog 6:05 p.m. Dec. 23, 2014 - Zacks.com
Bristol-Myers Oncology Drug Opdivo Receives FDA Approval - Analyst Blog 5:45 p.m. Dec. 23, 2014 - Zacks.com
Actavis' Antibiotic a Step Closer to EU Nod, CHMP Positive - Analyst Blog 5:51 p.m. Dec. 22, 2014 - Zacks.com
Actavis, Valeant Largely Avoid Gilead's Hepatitis Dive 5:23 p.m. Dec. 22, 2014 - Investors Business Daily
Cubist's Antibiotic Zerbaxa Wins FDA Nod for cUTI and cIAI - Analyst Blog 4:30 p.m. Dec. 22, 2014 - Zacks.com
Energy Sector Seen as Biggest Risk to Deal Flow in 2015 9:00 a.m. Dec. 22, 2014 - FOXBusiness
Actavis plc (ACT): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Dec. 22, 2014 - Zacks.com
Actavis 8-K Shows $1B Revolving Credit Facility Replacing Existing $750M Pact; Term Loan Credit Pact In 2 Tranches Of $2.75B Each 5:43 a.m. Dec. 22, 2014 - benzinga.com
10 Biggest Mergers and Acquisitions of 2014 3:15 a.m. Dec. 22, 2014 - InvestorPlace.com
Merrill Lynch Top Healthcare Stock Picks for 2015 2:00 p.m. Dec. 19, 2014 - 247WallSt.com
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo 10:53 a.m. Dec. 19, 2014 - Seeking Alpha
Baidu, Alibaba Among Top World Stocks Building Bases 5:09 p.m. Dec. 18, 2014 - Investors Business Daily
Emergent BioSolutions Buys EV-035 Series from Evolva - Analyst Blog 4:45 p.m. Dec. 18, 2014 - Zacks.com
9 Big Stocks That Doubled in 2014 11:19 a.m. Dec. 18, 2014 - 247WallSt.com
Tetraphase Jumps As 'Superbug' Drug Scores In Trial 10:54 a.m. Dec. 18, 2014 - Investors Business Daily

Timing is Crucial, Upside Analysis: Research Reports on Alder, Sky Solar, CNinsure, Raytheon, and Actavis 9:00 a.m. Dec. 29, 2014 - PR Newswire - PRF
Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 1:15 p.m. Dec. 24, 2014 - PR Newswire - PRF
Actavis and Adamas Announce FDA Approval of Namzaric™, a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride 8:00 a.m. Dec. 24, 2014 - PR Newswire - PRF
Actavis Names Jonathon Kellerman Executive Vice President, Global Chief Compliance Officer 9:24 a.m. Dec. 22, 2014 - PR Newswire - PRF
Actavis to Present at 33rd Annual J.P. Morgan Healthcare Conference 9:00 a.m. Dec. 22, 2014 - PR Newswire - PRF
XYDALBA™ (dalbavancin) Receives CHMP Positive Opinion for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Adults 4:15 p.m. Dec. 19, 2014 - PR Newswire - PRF
Actavis to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference 9:00 a.m. Dec. 19, 2014 - PR Newswire - PRF
Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Allergan Acquisition 7:30 a.m. Dec. 16, 2014 - PR Newswire - PRF
Actavis Will Appeal Injunction Requiring Continued Distribution of NAMENDA® IR 3:11 p.m. Dec. 15, 2014 - PR Newswire - PRF
Actavis Launches Generic Version of Celebrex® 9:28 a.m. Dec. 10, 2014 - PR Newswire - PRF
Anti-Infective Advisory Committee Recommends Approval Of Actavis' Ceftazidime-Avibactam 4:46 p.m. Dec. 5, 2014 - PR Newswire - PRF
No Wrinkles in Actavis' $66 Billion Deal to Buy Botox Maker Allergan, an Industrial Info News Alert 6:15 a.m. Dec. 3, 2014 - Marketwired
Stock Updates on Pharma Services - Avanir Pharma, Zoetis, Allergan, Mallinckrodt, and Actavis 8:30 a.m. Nov. 25, 2014 - PR Newswire - PRF
Critical Alerts For Gold Fields, Actavis, Trina Solar Limited, Alcoa and Herbalife Released By InvestorsObserver 9:31 a.m. Nov. 19, 2014 - PR Newswire - PRF
ALLERGAN, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout 10:32 a.m. Nov. 17, 2014 - PR Newswire - PRF
Valeant Comments On Allergan Announcement 9:29 a.m. Nov. 17, 2014 - PR Newswire - PRF
Actavis to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenue 9:15 a.m. Nov. 17, 2014 - PR Newswire - PRF
Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer 8:00 a.m. Nov. 17, 2014 - PR Newswire - PRF
Actavis Announces FDA Acceptance of sNDA for SAPHRIS® (asenapine) for the Treatment of Bipolar I Disorder in Pediatric Patients 8:00 a.m. Nov. 13, 2014 - PR Newswire - PRF
Actavis Names Maria Teresa Hilado Chief Financial Officer 4:15 p.m. Nov. 10, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

What to Expect: Your First Therapy Session Insights

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

ASTS Faces Crucial Deadline Amidst Legal Turmoil

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Pathalys' Phase 3 Data Shows Promise for CKD Drug

A Glimpse at Pathalys Pharma's Recent Win This is some groundbreaking stuff emerging from Pathalys Pharma. Their investigational drug, upacicalcet, has just clinched a significant victory in two crucial Phase 3 trials - PATH-1 and PATH-2 - aimed at treating Secondary Hyperparathyroidism (SHPT) in patients with end-stage kidney disease undergoing hemodialysis. With SHPT...

CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

World Young Scientist Summit 2026 in Wenzhou Kicks Off

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

DIRECTV Bags New NHL Deals: Stakes for Sports Fans

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Gildan Faces Lawsuit: Allegations of Deceptive Practices Shake Investors

Gildan's Troubles Unveiled The financial jungle can be a pretty treacherous place, and Gildan Activewear Inc. (NYSE: GIL) just found out how fickle the market can be. An 18.7% nosedive in Gildan's stock price after a securities fraud class action came knocking—if that isn't enough to stir up a hornet’s nest among investors, I don’t know what is. The Catalyst:...

Apalutamide Boosts Outlook for Prostate Cancer Treatment

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

John Wong's Decade as Estate Planning Specialist

One man's legacy isn’t built overnight, especially not in estate planning. And John L. Wong's decade of being a certified specialist by the State Bar of California tells a story of perseverance and grit. Now, at the helm of Modern Wealth Law in Irvine, California, Wong is a name that echoes through the halls of estate planning law with authority and respect. Creating...

Bio-Thera's New Data: A Game Changer for NSCLC?

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...